3.28  -0.12 (-3.53%)		12-12 16:00
Open: 3.63 High: 3.63 Volume: 47,813		Pre. Close: 3.4 Low: 3.28 Market Cap: 155(M)

Short term
Mid term
Targets	6-month :	4.51	1-year :	5.31
Resists	First :	3.86	Second :	4.55
Pivot price	3.25
Supports	First :	2.75	Second :	2.29
MAs	MA(5) :	3.19	MA(20) :	3.42
	MA(100) :	4.64	MA(250) :	5.72
MACD	MACD :	-0.3	Signal :	-0.4
%K %D	K(14,3) :	42.8	D(3) :	33.8
RSI	RSI(14): 41.5
52-week	High :	8.96	Low :	2.75

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NBTX ] has closed below upper band by 48.2%. Bollinger Bands are 22.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.63 - 3.65	3.65 - 3.67
Low:	3.24 - 3.26	3.26 - 3.28
Close:	3.25 - 3.28	3.28 - 3.31

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Wed, 11 Dec 2024
Voting Rights and Shares Capital of the Company - GlobeNewswire

Wed, 11 Dec 2024
Nanobiotix Reports 47.4M Shares Outstanding, Showcases Strong Patent Portfolio in Oncology Nanotech - StockTitan

Mon, 09 Dec 2024
Nanobiotix Phase 1 Cancer Treatment Shows Promising 23-Month Survival in Pancreatic Cancer Study - StockTitan

Thu, 28 Nov 2024
Nanobiotix (NASDAQ:NBTX) Shares Down 3.5% - Here's Why - MarketBeat

Wed, 13 Nov 2024
Nanobiotix Reports 47.4M Shares Outstanding, Updates Voting Rights Structure | NBTX Stock News - StockTitan

Tue, 12 Nov 2024
Nanobiotix Q3: Janssen Takes Lead in Phase 3 Trial, €53.2M Cash Position Extends Runway | NBTX Stock News - StockTitan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	47 (M)
Shares Float	21 (M)
Held by Insiders	0 (%)
Held by Institutions	13.5 (%)
Shares Short	30 (K)
Shares Short P.Month	31 (K)

EPS	-0.78
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.47
Profit Margin	-79.4 %
Operating Margin	-253.4 %
Return on Assets (ttm)	-22.1 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	182.1 %
Gross Profit (p.s.)	0
Sales Per Share	0.89
EBITDA (p.s.)	-0.48
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-4.21
PEG Ratio	0
Price to Book value	-7.14
Price to Sales	3.68
Price to Cash Flow	-149.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.